Clinical course of neuroendocrine tumors with different origins (the Pancreas, Gastrointestinal Tract, and Lung)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 6, 2012, Pages 549-556

  Kim, Su Jung ^a,b   Kim, Jin Won ^a,b   Oh, Do Youn ^a,b   Han, Sae Won ^a   Lee, Se Hoon ^a   Kim, Dong Wan ^a   Im, Seock Ah ^a   Kim, Tae You ^a   Heo, Dae Seog ^a   Bang, Yung Jue ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

neuroendocrine tumor; origin; prognosis; treatment outcome

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; NEURON SPECIFIC ENOLASE;

ADULT; AGE; AGED; BONE METASTASIS; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOID SYNDROME; COURSE EVALUATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LUNG TUMOR; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; RECURRENCE RISK; REVIEW; SEX DIFFERENCE; SURVIVAL TIME; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME; URINE LEVEL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BONE NEOPLASMS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84870255588     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31821dee0f     Document Type: Review

References (20)

1. Oberndorfer S. Karzinoide tumoren des dunndarms. Frankf Z Pathol. 1907;1:425-429.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after ''carcinoid'': Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
3. Tomassetti P, Campana D, Piscitelli L, et al. Endocrine pancreatic tumors: Factors correlated with survival. Ann Oncol. 2005;16: 1806-1810. (Pubitemid 41631244)
4. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13:2986-2991. (Pubitemid 46849574)
5. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol. 2008;26:4311-4318.
6. Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: Definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol. 2005;19:491-505.
7. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet. 1963;1:238-239.
8. Solcia E, Kloppel G, Sobin LH. World Health Organization: INTERNATIONAL Histological Classification of Tumours: HISTOLOGICAL Typing of Endocrine Tumours. Berlin: SPRINGER; 2000.
9. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: A prognostic spectrum. J Clin Oncol. 2006;24:70-76. (Pubitemid 46630496)
10. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
11. Quaedvlieg PF, Visser O, Lamers CB, et al. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol. 2001;12: 1295-1300. (Pubitemid 32994760)
12. Oberg K. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes. 2009;16:72-78.
13. Ceppi P, Volante M, Ferrero A, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res. 2008;14:1059-1064. (Pubitemid 351302551)
14. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion. 2000;62(suppl 1): 73-78. (Pubitemid 30665943)
15. Bettini R, Boninsegna L, Mantovani W, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008;19:903-908. (Pubitemid 351627305)
16. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: An analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633-2642. (Pubitemid 34575635)
17. Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009;89:471-476.
18. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8:685-690. (Pubitemid 27372168)
19. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858-865. (Pubitemid 29399927)
20. Ito T, Tanaka M, Sasano H, et al. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol. 2007;42:497-500. (Pubitemid 47050014)